Estelle Ayme-Dietrich1, Roland Lawson1, Francine Côté2,3, Claudia de Tapia1, Sylvia Da Silva1, Claudine Ebel4, Béatrice Hechler5, Christian Gachet5, Jérome Guyonnet6, Hélène Rouillard7, Jordane Stoltz7, Emily Quentin8,9,10, Sophie Banas8,9,10, François Daubeuf11, Nelly Frossard11, Bernard Gasser7, Jean-Philippe Mazzucotelli12, Olivier Hermine2,3, Luc Maroteaux8,9,10, Laurent Monassier1. 1. Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire (EA7296), Faculté de Médecine, Fédération de Médecine Translationnelle, Université et Centre Hospitalier de Strasbourg, Strasbourg, France. 2. Department of Hematology, Institut Imagine, INSERM U1183 CNRS ERL 8254, Université Paris Descartes-Sorbonne Paris Cité, Hôpital Universitaire Necker Enfants Malades, Paris, France. 3. Laboratory of Excellence GR-Ex, Paris, France. 4. Department of Flow Cytometry, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France. 5. Etablissement Français du sang (EFS) Alsace, Inserm U949, Strasbourg, France. 6. Pharmaceutical Research Department, CEVA Santé Animale, Libourne, France. 7. Laboratoire de Pathologie, Centre Hospitalier Emile Muller, Mulhouse, France. 8. INSERM UMR-S 839, Paris, France. 9. Sorbonne Université́, UPMC Univ Paris 06, Paris, France. 10. Institut du Fer à Moulin, Paris, France. 11. Laboratoire d'Innovation Thérapeutique, UMR7200 CNRS/Université de Strasbourg, LabExMedalis, Faculté de Pharmacie, Illkirch, France. 12. Service de Chirurgie Cardiaque, Centre Hospitalier de Strasbourg, Strasbourg, France.
Abstract
BACKGROUND AND PURPOSE: Valvular heart disease (VHD) is highly prevalent in industrialized countries. Chronic use of anorexigens, amphetamine or ergot derivatives targeting the 5-HT system is associated with VHD. Here, we investigated the contribution of 5-HT receptors in a model of valve degeneration induced by nordexfenfluramine, the main metabolite of the anorexigens, dexfenfluramine and benfluorex. EXPERIMENTAL APPROACH: Nordexfenfluramine was infused chronically (28 days) in mice ((WT and transgenic Htr2B -/- , Htr2A -/- , and Htr2B/2A -/- ) to induce mitral valve lesions. Bone marrow transplantation was also carried out. Haemodynamics were measured with echocardiography; tissues and cells were analysed by histology, immunocytochemistry, flow cytometry and RT -qPCR. Samples of human prolapsed mitral valves were also analysed. KEY RESULTS: Chronic treatment of mice with nordexfenfluramine activated 5-HT2B receptors and increased valve thickness and cell density in a thick extracellular matrix, mimicking early steps of mitral valve remodelling. Lesions were prevented by 5-HT2A or 5-HT2B receptor antagonists and in transgenic Htr2B -/- or Htr2A/2B -/- mice. Surprisingly, valve lesions were mainly formed by numerous non-proliferative CD34+ endothelial progenitors. These progenitors originated from bone marrow (BM) as revealed by BM transplantation. The initial steps of mitral valve remodelling involved mobilization of BM-derived CD34+ CD31+ cells by 5-HT2B receptor stimulation. Analysis of human prolapsed mitral valves showing spontaneous degenerative lesions, demonstrated the presence of non-proliferating CD34+ /CD309+ /NOS3+ endothelial progenitors expressing 5-HT2B receptors. CONCLUSIONS AND IMPLICATIONS: BM-derived endothelial progenitor cells make a crucial contribution to the remodelling of mitral valve tissue. Our data describe a new and important mechanism underlying human VHD.
BACKGROUND AND PURPOSE:Valvular heart disease (VHD) is highly prevalent in industrialized countries. Chronic use of anorexigens, amphetamine or ergot derivatives targeting the 5-HT system is associated with VHD. Here, we investigated the contribution of 5-HT receptors in a model of valve degeneration induced by nordexfenfluramine, the main metabolite of the anorexigens, dexfenfluramine and benfluorex. EXPERIMENTAL APPROACH: Nordexfenfluramine was infused chronically (28 days) in mice ((WT and transgenic Htr2B -/- , Htr2A -/- , and Htr2B/2A -/- ) to induce mitral valve lesions. Bone marrow transplantation was also carried out. Haemodynamics were measured with echocardiography; tissues and cells were analysed by histology, immunocytochemistry, flow cytometry and RT -qPCR. Samples of human prolapsed mitral valves were also analysed. KEY RESULTS: Chronic treatment of mice with nordexfenfluramine activated 5-HT2B receptors and increased valve thickness and cell density in a thick extracellular matrix, mimicking early steps of mitral valve remodelling. Lesions were prevented by 5-HT2A or 5-HT2B receptor antagonists and in transgenic Htr2B -/- or Htr2A/2B -/- mice. Surprisingly, valve lesions were mainly formed by numerous non-proliferative CD34+ endothelial progenitors. These progenitors originated from bone marrow (BM) as revealed by BM transplantation. The initial steps of mitral valve remodelling involved mobilization of BM-derived CD34+ CD31+ cells by 5-HT2B receptor stimulation. Analysis of human prolapsed mitral valves showing spontaneous degenerative lesions, demonstrated the presence of non-proliferating CD34+ /CD309+ /NOS3+ endothelial progenitors expressing 5-HT2B receptors. CONCLUSIONS AND IMPLICATIONS: BM-derived endothelial progenitor cells make a crucial contribution to the remodelling of mitral valve tissue. Our data describe a new and important mechanism underlying human VHD.
Authors: Bo Jian; Jie Xu; Jeanne Connolly; Rashmin C Savani; Navneet Narula; Bruce Liang; Robert J Levy Journal: Am J Pathol Date: 2002-12 Impact factor: 4.307
Authors: Kartik Balachandran; Marina A Bakay; Jeanne M Connolly; Xuemei Zhang; Ajit P Yoganathan; Robert J Levy Journal: Ann Thorac Surg Date: 2011-07 Impact factor: 4.330
Authors: Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath Journal: Br J Pharmacol Date: 2015-07 Impact factor: 8.739
Authors: Mordehay Vaturi; Leor Perl; Dorit Leshem-Lev; Oshrat Dadush; Tamir Bental; Yaron Shapira; Idit Yedidya; Gabi Greenberg; Ran Kornowski; Alexander Sagie; Alexander Battler; Eli I Lev Journal: Am J Cardiol Date: 2011-05-06 Impact factor: 2.778
Authors: Richard P Visconti; Yasuhiro Ebihara; Amanda C LaRue; Paul A Fleming; Tim C McQuinn; Masahiro Masuya; Hitoshi Minamiguchi; Roger R Markwald; Makio Ogawa; Christopher J Drake Journal: Circ Res Date: 2006-02-02 Impact factor: 17.367
Authors: S E Cremer; N E Zois; S G Moesgaard; N Ravn; S Cirera; J L Honge; M H Smerup; J M Hasenkam; E Sloth; P S Leifsson; T Falk; M A Oyama; C Orton; T Martinussen; L H Olsen Journal: Vet J Date: 2014-12-23 Impact factor: 2.688
Authors: Hideyuki Beppu; Rajeev Malhotra; Yuko Beppu; John J Lepore; Michael S Parmacek; Kenneth D Bloch Journal: Dev Biol Date: 2009-05-03 Impact factor: 3.582
Authors: Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari Journal: Cardiovasc Pathol Date: 2020-01-07 Impact factor: 2.185
Authors: J Ethan Joll; Cynthia R Clark; Christine S Peters; Michael A Raddatz; Matthew R Bersi; W David Merryman Journal: PLoS One Date: 2020-11-25 Impact factor: 3.240